CTI BIOPHARMA CORP
CTI BIOPHARMA CORP (CTIC): 2 pipeline candidates · ~6 mo cash runway · 1 clinical trial. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
6.3 months
0% dilution
Lead: Approved
2 candidates
N/A
N/A
A transparent, data-derived signal for CTI BIOPHARMA CORPacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$24.2M
Quarterly Burn
$31.1M
Runway
6.3 mo
Revenue
$24.1M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (2 candidates)
| Drug | Phase |
|---|---|
| pacritinib | Phase 3 |
| vonjo | Approved |
Frequently asked questions
How many drug candidates are in CTI BIOPHARMA CORP's pipeline?
CTI BIOPHARMA CORP (CTIC) has 2 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is CTI BIOPHARMA CORP's lead drug candidate?
CTI BIOPHARMA CORP's most advanced tracked candidate is pacritinib (Phase 3) for Severe COVID-19.
What is CTI BIOPHARMA CORP's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, CTI BIOPHARMA CORP has approximately 6.3 months of cash runway.
Who is the CEO of CTI BIOPHARMA CORP?
Adam R. Craig M.D. is the chief executive officer of CTI BIOPHARMA CORP (CTIC).
Get the full picture on CTI BIOPHARMA CORP
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.